Implantable nanochannel delivery devices

Abstract

An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

1 . An implantable device, comprising:
 a tubular body defining a first opening and a reservoir, and   a nanochanneled membrane disposed within the first opening,   wherein the tubular body has a length of less than 5 mm.   
     
     
         2 . The device of  claim 1 , wherein the nanochanneled membrane comprises nanochannels from 2.5 nm to 100 nm in diameter. 
     
     
         3 . The device of  claim 1 , wherein the nanochanneled membrane comprises nanochannels at a density of greater than 100,000 nanochannels mm −2 . 
     
     
         4 . The device of  claim 1 , wherein the tubular body is titanium, tungsten, gold, or stainless steel. 
     
     
         5 . The device of  claim 1 , wherein the tubular body has a diameter of less than 2 mm. 
     
     
         6 . The device of  claim 1 , wherein the reservoir has volume of from 0.5 μL to 10 μL. 
     
     
         7 . The device of  claim 1 , wherein the tubular body defines a second opening, and the second opening is sealed with silicone, plastic, or rubber. 
     
     
         8 . The device of  claim 1 , wherein the reservoir comprises a liquid or powder. 
     
     
         9 . The device of  claim 1 , wherein the reservoir comprises an anticancer agent, radioactive agent, imaging agent, and/or gene therapy agent. 
     
     
         10 . The device of  claim 1 , wherein the reservoir comprises an antibody or immunoglobulin. 
     
     
         11 . The device of  claim 1 , wherein the reservoir comprises  90 Y,  177 Lu,  18 F,  64 Cu,  67 Cu,  89 Zr,  124 I,  123 I,  152 Eu,  99 Tc,  225 Ac,  68 Ga,  111 In, or  192 Ir. 
     
     
         12 . The device of  claim 1 , wherein the reservoir comprises PD1, IgG, CTLA4, microRNA, PDL1, CD73, antiCD40 agonist, antiPD1 antibody, or pDox. 
     
     
         13 . The device of  claim 1 , wherein the reservoir comprises doxorubicin, OX86, FGK45, or Magnevist. 
     
     
         14 . A method of treating a cancer, comprising: implanting into to a subject the device of  claim 1 , wherein the device comprises an effective amount of an anticancer agent, radioactive agent, imaging agent, and/or gene therapy agent in the reservoir. 
     
     
         15 . The method of  claim 14 , wherein the device is monitored radiographically during implantation. 
     
     
         16 . The method of  claim 14 , further comprising implanting a second device, wherein the second device comprises the device of  claim 1 . 
     
     
         17 . The method of  claim 14 , further comprising irradiating the subject with radiation. 
     
     
         18 . The method of  claim 14 , wherein the cancer is rectal, cervical, lung, melanoma, prostate, or pancreatic cancer. 
     
     
         19 . A method of collecting a sample from a subject, comprising: implanting a subject the device of  claim 1 ; withdrawing the device from the subject; and isolating from the device the sample.